Back to User profile » Professor Wen Xia
Papers published by Professor Wen Xia:
Significance of Pre-Treatment CALLY Score Combined with EBV-DNA Levels for Prognostication in Non-Metastatic Nasopharyngeal Cancer Patients: A Clinical Perspective
Jiang T, Sun H, Xu T, Xue S, Xia W, Xiao X, Wang Y, Guo L, Lin H
Journal of Inflammation Research 2024, 17:3353-3369
Published Date: 23 May 2024
Does the Dose of Standard Adjuvant Chemotherapy Affect the Triple-negative Breast Cancer Benefit from Extended Capecitabine Metronomic Therapy? An Exploratory Analysis of the SYSUCC-001 Trial
Chen Y, Li WX, Wu JH, Chen GH, Yang CM, Lu H, Wang X, Wang SS, Huang H, Cai L, Zhao L, Peng RJ, Lin Y, Tang J, Zeng J, Zhang LH, Ke YL, Wang XM, Liu XM, Zhang AQ, Xu F, Bi XW, Huang JJ, Li JB, Pang DM, Xue C, Shi YX, He ZY, Lin HX, An X, Xia W, Cao Y, Guo Y, Hong RX, Jiang KK, Zhong YY, Zhang G, Tienchaiananda P, Oikawa M, Yuan ZY, Chen QJ
Breast Cancer: Targets and Therapy 2024, 16:223-231
Published Date: 12 April 2024
An Aging-Related Gene Signature-Based Model for Risk Stratification and Prognosis Prediction in Breast Cancer
Yuan J, Duan F, Zhai W, Song C, Wang L, Xia W, Hua X, Yuan Z, Bi X, Huang J
International Journal of Women's Health 2021, 13:1053-1064
Published Date: 3 November 2021
Establishment of Prognostic Nomograms for Predicting the Survival of HR-Positive, HER2-Negative Metastatic Breast Cancer Patients Treated with Everolimus
Duan F, Song C, Ma Y, Jiang K, Xu F, Bi X, Huang J, Hong R, Huang Z, Lu Q, Yuan Z, Wang S, Xia W
Drug Design, Development and Therapy 2021, 15:3463-3473
Published Date: 10 August 2021
Clinical value of circulating ESR1 mutations for patients with metastatic breast cancer: a meta-analysis
Zhang K, Hong R, Xu F, Xia W, Kaping L, Qin G, Zheng Q, Lu Q, Shi YX, Yuan ZY, Wang SS
Cancer Management and Research 2018, 10:2573-2580
Published Date: 14 August 2018